Recurrent urinary tract infections and their effective intermittent therapy with the drug CYSTO-AURIN® (Solidago virgaurea)

Kostjev F.I.,Lukinuk E.I.,Shostak M.V.

Main
Publications
Recurrent urinary tract infections and their effective intermittent therapy with the drug CYSTO-AURIN® (Solidago virgaurea)

July 31, 2018

891

Nephrology and Urology

Kostjev F.I.

Lukinuk E.I.

Shostak M.V.

Specialities :

Nephrology and Urology

Resume

The article presents the results of the study of the clinical and laboratory efficacy of intermittent therapy with the drug Cysto-aurin® (Solidago virgaurea), as well as its effect on the quality of life of patients with recurrent urinary tract infections (UTIs). There are evidence of a significant reduction in a number of relapses of IMPs by 92.3% during 6 months of treatment with the drug. The positive effect of the therapy on pyuria, reduction of proinflammatory activity and statistically significant reduction of manifestations of inflammation in the urinary system are shown. The reduction of leukocyturia was 73.4%. A clinically and statistically significant bacteriostatic effect was noted, both in treatment (41.0%) and 6-month follow-up period (30.3%), as well as the antibacterial effect in relation to clinically significant uropathogens, a significant reduction in the severity of the key clinical symptoms of the recurrent IMPs, a significant improvement in the quality of life of patients.

M.V. Shostak, F.I. Kostjev, E.I. Lukinuk

Key words: urinary tract infections, chronic recurrent cystitis, Solidago virgaurea, Cysto-aurin^®.

Published: 04.09.2018

References:

Shostak M.V., Kostev F.I., Lukinyuk E.I. (2018) Effektivnaya profilaktika chasto retsidiviruyuschih infektsiy mochevyih putey deystviem preparata zolotarnika obyiknovennogo (Solidago virgaurea) Tsisto-aurin. Pochki, 3.
Brantner A. (1999) The antimicrobial activity of Solidago-containing phytourologica. Drogen-report, 12: 27–28.
Choi S.Z., Choi S.U., Bae S.Y. et al. (2005) Immunobiological activity of a new benzyl benzoate from the aerial part sof Solidago virgaurea var. gigantean. Arch. Pharm. Res., 28: 49–54.
Dason S., Dason J.T., Kapoor A. (2011) Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can. Urol. Assoc. J., 5(5): 316–322.
Deng Y., Zhao Y., Padilla-Zakour O., Yang G. (2015) Polyphenols, antioxidant and antimicrobial activities of leaf and bark extracts of Solidago canadensis L. Ind. Crops Prod., 74: 803–809.
Dwyer P.L., O’Reilly M. (2002) Recurrent urinary tract infection in the female. Curr. Opin. Obstet. Gynecol., 14(5): 537–543.
Ejrnæs K. (2011) Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan. Med. Bull., 58(4): B4187.
European Goldenrod (2013) Herbal Medicines. 4th ed., 928 p.
European Medicines Agency (2008) Assessment report on Solidago virgaurea L. herba (http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2009/12/WC500018161.pdf).
Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol., 13(5): 269–284.
Foxman B. (2014) Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am., 28(1): 1–13.
Foxman B., Barlow R., D’Arcy H. et al. (2000) Urinary tract infection: self-reported incidence and associated costs. Ann. Epidemiol., 10(8): 509–515.
Frumenzio E., Maglia D., Salvini E. et al. (2013) Role of phytotherapy associated with antibiotic prophylaxis in female patients with recurrent urinary tract infections. Arch. Ital. Urol. Androl., 85(4): 197–199.
Glover M., Moreira C.G., Sperandio V., Zimmern P. (2014) Recurrent urinary tract infections in healthy and nonpregnant women. Urol. Sci., 25(1): 1–8.
Grabe M., Bartoletti R., Bjerklund Johansen T.E. et al. (2015) Guidelines on Urological Infections (https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf).
Grimes C.L., Lukacz E.S. (2011) Urinary tract infections. Female Pelvic Med. Reconstr. Surg., 17(6): 272–278.
Kalemba D. (2000) Constituents and biological activity of the essential oils of some Solidago and Artemisia species. Scientific Papers Technical University of Lodz, 857: 1–118.
Kołodziej B., Kowalski R., Kędzia B. (2011) Antibacterial and antimutagenic activity of extracts aboveground parts of three Solidago species: Solidago virgaurea L., Solidago сanadensis L. and Solidago gigantean Ait. J. Med. Plants Res., 5(31): 6770–6779.
Laurençon L., Sarrazin E., Chevalier M. et al. (2013) Triterpenoid saponins from the aerial parts of Solidago virgaurea alpestris with inhibiting activity of Candida albicans yeast-hyphal conversion. Phytochemistry, 86: 103–111.
Melzig M.F. (2000) New aspects for understanding the mechanism of the aquaretic effects of birch leaves and goldenrod. Zeitschrift fur Phytotherapie, 21(4): 193–196.
Melzig M.F. (2004) Goldenrod — a classical exponent in the urological phytotherapy. Wien Med. Wochenschr., 154(21–22): 523–527.
Melzig M.F., Löser B., Bader G., Papsdorf G. (2000) Echtes Goldenrutenkraut als entzündungshemmende Droge. Z. Phytother., 21: 67–70.
Meyer B., Schneider W., Elstner E.F. (1995) Antioxidative properties of alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea. Arzneimittelforschung, 45(2): 174–176.
Pepeljnjak S., Kustrak D., Vukusic I. (1998) Investigation of the antimycotic activity of Solidago virgaurea and Solidago gigantea extracts. Pharm. Pharmacol. Lett., 8: 85–86.
Plohmann B., Bader G.T., Hiller K., Franz G. (1997) Immunomodulatory and antitumoral effects of triterpenoid saponins. Pharmazie, 12: 953–957.
Plohmann B., Franz G., Bader G., Hiller K. (1999) Immunmodulatorische und antitumorale Aktivität von Triterpensaponinen aus Solidago virgaurea L. Drogenreport, 12: 29–30.
Sampson J.H., Phillipson J.D., Bowery N.G. et al. (2000) Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological activity in receptor binding assays. Phytother. Res., 14(1): 24–29.
Schakau D. (2014) Solidago Steiner® Tabletten. Solidago Steiner® Lösung und Harntee Steiner®. Portfolio-Schulung.
Starks C.M., Williams R.B., Goering M.G. et al. (2010) Antibacterial clerodane diterpenes from Goldenrod (Solidago virgaurea). Phytochemistry, 71(1): 104–109.
Strehl E., Schneider W., Elstner E.F. (1995) Inhibition of dihydrofolate reductase activity by alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea. Arzneimittelforschung, 45(2): 172–173.
Thiem B., Goślińska O. (2002) Antimicrobial activity of Solidago virgaurea L. from in vitro cultures. Fitoterapia, 73(6): 514–516.
van der Starre W.E., van Nieuwkoop C., Paltansing S. et al. (2011) Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J. Antimicrob. Chemother., 66(3): 650–656.
Westendorf J., Vahlensieck W. (1981) Spasmolytische und kontraktile Einflüsse eines pflanzlichen Kombinations-präparates auf die glatte Muskulatur des isolierten Meerschweinchendarms. Arzneim Forsch/Drug Res., 31: 40–43.